Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 2
18+
4 sites in GA, MD, NE +1
What this study is about
This Phase 2 study is testing Dexamethasone in people with multiple myeloma. The primary outcome being measured is Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dexamethasone, pomalidomide
injection, ocular, oral (Oral Capsule)
Primary: Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC)
Secondary: Complete Response (CR) or better rate, defined as the percentage of patients with a confirmed CR or better, based on IMWG criteria and assessed by investigator and ICR, Duration of Response (DoR), defined as the duration of overall response by investigator and ICR, Incidence of treatment-emergent adverse events (TEAEs), vital signs and laboratory abnormalities, ORR, defined as the percentage of patients with a confirmed PR or better, based on IMWG criteria assessed by Investigator, Overall Survival (OS), defined as the time from enrolment to the date of death due to any cause, Progression Free Survival (PFS), defined as the time from enrolment until the earliest date of Progressive Disease (PD), or death due to any cause, and assessed by investigator and ICR, Time to Response (TTR), defined as time to confirmed PR or better, by investigator and ICR
Oncology